There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PD-1


PD-1 Molecule Information

Name:Programmed cell death protein 1
Target Synonym:Programmed cell death protein 1?PDCD1?hPD-1?PD1?CD_antigen=CD279?Protein PD-1
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:64
Lastest Research Phase:Approved

PD-1 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
PD1-HP2F2 Human PE-Labeled Human PD-1 / PDCD1 Protein, Fc Tag, His Tag (recommended for neutralizing assay)
PD1-H5255 Human Human PD-1 / PDCD1 Protein, Mouse IgG2a Fc Tag (HPLC-verified)
PD1-H522a Human Human PD-1 / PDCD1 Protein, His Tag, low endotoxin (HPLC-verified)
EPC-V1 Monkey ELISA Assay Kit for Anti-PD-1 h-mAb in Monkey Serum
EPM-V1 Mouse ELISA Assay Kit for Anti-PD-1 h-mAb in Mouse Serum
PD1-H5259 Human Human PD-1 / PDCD1 Protein, Llama IgG2b Fc Tag, low endotoxin
EPH-V1 Human ELISA Assay Kit for Anti-PD-1 h-mAb in Human Serum
PD1-H82F1 Human Biotinylated Human PD-1 / PDCD1 Protein, Fc,Avitag™
PD1-RB5251 Rabbit Rabbit PD-1 / PDCD1 Protein, Fc Tag
PD1-M52A4 Mouse Mouse PD-1 / PDCD1 Protein, mouse IgG2a Fc Tag, low endotoxin
PD1-R52H2 Rat Rat PD-1 / PDCD1 Protein, His Tag
PD1-H82E4 Human Biotinylated Human PD-1 / PDCD1 Protein, Avitag™,His Tag (recommended for biopanning)
PD1-R52H0 Rabbit Rabbit PD-1 / PDCD1 Protein
PD1-M82F4 Mouse Biotinylated Mouse PD-1 / PDCD1, Fc Tag, Avi Tag (Avitag™)
PD1-R5253 Rat Rat PD-1 / PDCD1 Protein, Fc Tag
PD1-M5259 Mouse Mouse PD-1 / PDCD1 Protein, Fc Tag
PD1-H5284 Human Human PD-1 / PDCD1 Protein, Strep Tag
PD1-H82F2 Human Biotinylated Human PD-1 / PDCD1, His Tag & Fc Tag, Avi Tag (Avitag™)
PD1-HC214 Human Human PD-1 / PDCD1 Protein, Tag Free, Full Length
PD1-M5228 Mouse Mouse PD-1 / PDCD1 Protein, His Tag
PD1-C5254 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, Fc Tag
PD1-C5223 Cynomolgus Cynomolgus PD-1 / PDCD1 Protein, His Tag
PD1-H5257 Human Human PD-1 / PDCD1 Protein, Fc Tag, low endotoxin (HPLC-verified)
PD1-H5221 Human Human PD-1 / PDCD1 Protein, His Tag (HPLC verified)

PD-1 Molecule Synonym Name


PD-1 Molecule Background

Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-¦Ã. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-¦Ã by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-¦Ã secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

PD-1 References

PD-1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Toripalimab JS-001; TAB-001,JS001; JS 001 Approved Shanghai Junshi Biosciences, Suzhou Zhonghe Toripalimab Injection cfda Metastatic melanoma 2018-12-17 Metastatic melanoma Details
Pembrolizumab MK-3475,MK3475,SCH-900475,h409A11 Approved Merck Sharp & Dohme KEYTRUDA fda Non small cell lung cancer (NSCLC), Metastatic melanoma, Head and neck cancer, Advanced melanoma MERCK SHARP DOHME 2014-09-04 Gastric cancer, Colorectal neoplasms, Primary mediastinal B cell lymphoma, Urothelial cancer, Solid tumours, Squamous cell carcinoma of head and neck cancer (SCCHN), Hepatocellular carcinoma (HCC), Microsatellite instability-high cancer, Advanced melanoma, Head and neck cancer, Hodgkin lymphoma, Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Diffuse large B cell lymphoma, Merkel cell carcinoma, Metastatic melanoma, Cervical carcinoma, Melanoma Details
Nivolumab MDX-1106; BMS-936558; BMS-936558-01; ONO-4538; ono-0123,MDX1106,BMS936558,ONO4538 Approved Ono Pharmaceutical, Bristol-Myers Squibb Nivolumab 日本 Metastatic melanoma 小野制药 2014-07-04 00:00:00.0 Gastric cancer, Advanced renal cell carcinoma (RCC), Metastatic non-small cell lung cancer, Urothelial cancer, Hepatocellular carcinoma (HCC), Head and neck cancer, Hodgkin lymphoma, Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Renal cell carcinoma, Metastatic melanoma, Metastatic colorectal cancer (CRC), Renal carcinoma, Melanoma Details
Sintilimab IBI-308,IBI308 Approved Innovent Biologics, Lilly Sintilimab Injection cfda Hodgkin lymphoma 2018-12-24 Hodgkin lymphoma Details
Cemiplimab REGN-2810; SAR-439684,REGN2810; SAR439684 Approved Regeneron Pharmaceutical, Sanofi LIBTAYO fda REGENERON PHARMACEUTICALS 2018-09-28 Metastatic cutaneous squamous cell carcinoma Details
Camrelizumab HR-301210; INCSHR-1210; SHR-1210,HR301210; INCSHR1210; SHR1210 Approved Jiangsu Hengrui Medicine, Suzhou Shengdiya Camrelizumab for Injection cfda Hodgkin lymphoma 2019-05-29 Hodgkin lymphoma Details

PD-1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Spartalizumab PDR-001 Phase Ⅲ Novartis Myelodysplastic syndrome (MDS), Nasopharyngeal cancer, Neuroendocrine tumors (NET), Breast cancer, Solid tumours, Multiple myeloma (MM), Colorectal cancer, Acute myeloid Leukemia (AML), Non-small cell lung cancer associated anorexia or cachexia, Lymphoma, Hepatocellular carcinoma (HCC), Ovarian cancer, Melanoma Details
INSIX RA (Indus Biotech) Phase Not Specified Indus Biotech Private Limited Inflammation, Rheumatoid arthritis (RA) Details
Pidilizumab CT-011; MDV-9300 Phase Ⅱ Glioma, Diffuse large B cell lymphoma, Prostate cancer, Follicular lymphoma, Multiple myeloma (MM), Colorectal cancer, Acute myeloid Leukemia (AML), Hepatocellular carcinoma (HCC), Renal carcinoma, HCV infection, Pancreatic cancer, Melanoma Details
CS-1003 CS-1003,CS1003 Phase Ⅰ CStone Pharmaceuticals Solid tumours Details
BI-754091 BI-754091,BI 754091,BI754091 Phase Ⅱ Boehringer Ingelheim Solid tumours Details
Cetrelimab JNJ-63723283 Phase Ⅲ Johnson & Johnson Multiple myeloma (MM) Details
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) Phase Ⅰ Marino Biotechnology, Chengdu Galaxy Biomed, Peking University B-cell lymphoma Details
AK-104 AK-104,AK104 Phase Ⅱ Akeso Biopharma Solid tumours Details
PD-1 knockout EBV-CTL (Nanjing Medical University) Phase Ⅱ Nanjing Medical University Nasopharyngeal cancer, Gastric cancer, Diffuse large B cell lymphoma, Lymphoma, Hodgkin lymphoma Details
Genolimzumab CBT-501; GB-226 Phase Ⅱ Genor Biopharma, CBT Thymic tumor, Solid tumours, Soft tissue sarcoma, Peripheral T cell lymphoma (PTCL), Non-Hodgkin B-cell lymphomas, Cervical carcinoma Details
609-A 609-A Phase Ⅰ 3SBio Solid tumours Details
CA-170 CA-170; AUPM-170 Phase Ⅱ Aurigene, Curis Cancer Details
Nivolumab/Relatlimab BMS-936558/BMS-986016; BMS-986213 Phase Ⅲ Bristol-Myers Squibb Melanoma Details
REMD-288 REMD-288 Preclinical REMD Biotherapeutics, Buchang Pharma Cancer Details
SL-279252 SL-279252 Phase Ⅰ Shattuck Labs Gastric adenocarcinoma, Non small cell lung cancer (NSCLC), Diffuse large B cell lymphoma, Renal cell carcinoma, Urothelial cancer, Solid tumours, Squamous cell carcinoma of head and neck cancer (SCCHN), Hodgkin lymphoma, Gastroesophageal junction adenocarcinoma, Melanoma Details
INCB-086550 INCB-086550 Phase Ⅰ Incyte Solid tumours Details
Dostarlimab ANB-011; TSR-042; WBP-285 Phase Ⅲ AnaptysBio, Tesaro, GlaxoSmithKline Fallopian tube cancer, Peritoneum cancer, Ovarian cancer Details
AK-105 AK-105,AK105; AK 105 Phase Ⅲ Akeso Biopharma Metastatic non-small cell lung cancer, Nasopharyngitis, Solid tumours, Hepatocellular carcinoma (HCC), Hodgkin lymphoma Details
AK-103 AK-103; HX-008 Phase Ⅱ Akeso Biopharma, Taizhou Hanzhong Biomed, Hansi Biological Pharmaceutical Gastric cancer, Solid tumours, Microsatellite instability-high cancer, Melanoma Details
MiHA-loaded PD-L silenced DC vaccination (Radboud University) Phase Ⅱ Radboud University Multiple myeloma (MM), Acute myeloid Leukemia (AML), Non-Hodgkin's lymphoma (NHL), Chronic myeloid leukemia (CML ) Details
F-520 (Shandong New age Pharma) F-520,F 520,F520 Phase Ⅰ Shandong Xinshidai Pharmaceutical Solid tumours, Lymphoma, Cancer Details
AMP-224 AMP-224; AMP-244; GSK-2661380,2661380 Phase Ⅰ Amplimmune, MedImmune, National Cancer Institute, GlaxoSmithKline Solid tumours, Colorectal cancer Details
Balstilimab AGEN-2034 Phase Ⅱ Agenus, Ludwig Institute for Cancer Research Solid tumours, Cervical carcinoma Details
INCMGA-0012 INCMGA-0012; MGA-012,MGA012; MGA 012 Phase Ⅱ MacroGenics, Incyte, Zai Lab Merkel cell carcinoma, Anal cancer Details
T3011疱疹病毒(深圳市亦诺微医药) IND Filing Cancer Details
Recombinant human anti-PD-1 monoclonal antibody(Sumgen) SG-001 Phase Ⅰ Hangzhou sumgen biotechnology Solid tumours Details
EDP-1503 EDP-1503 Phase Ⅱ University of Chicago, Evelo Biosciences, Merck Sharp & Dohme Melanoma Details
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) Phase Ⅰ HengRui YuanZheng Biotechnology Solid tumours Details
MEDI-0680 AMP-514; MEDI-0680,AMP514; MEDI0680 Phase Ⅱ MedImmune Solid tumours Details
AB-122 AB-122,AB 122; AB122 Phase Ⅰ Arcus Biosciences Solid tumours Details
Sym-021 Sym-021,Sym 021; Sym021 Phase Ⅰ Symphogen Solid tumours, Lymphoma Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shandong Xinshidai Pharmaceutical) Phase Ⅰ Shandong Xinshidai Pharmaceutical Solid tumours Details
Programmed cell death 1 antibody (Sun Yat-sen University) Phase Ⅱ Sun Yat-sen University Hepatocellular carcinoma (HCC) Details
STW204单抗 STW-204 Phase Ⅰ Stainwei Solid tumours Details
Millamolecule Phase Ⅰ Bristol-Myers Squibb Immunological disorders Details
RO-7121661 RG-7769; RO-7121661 Phase Ⅱ Roche Non small cell lung cancer (NSCLC), Solid tumours, Melanoma Details
XmAb20717 XmAb-20717,XmAb 20717 Phase Ⅰ Xencor Solid tumours Details
CC-90006 CC-90006,CC90006 Phase Ⅰ AnaptysBio, Celgene Autoimmune diseases, Psoriasis Details
Recombinant humanized anti-PD-1 monoclonal antibody (Bio-Thera) BAT-1306,BAT1306 Phase Ⅱ Bio-Thera Solutions Gastric cancer, Colorectal neoplasms, Solid tumours, Liver cancer Details
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) Phase Ⅰ Anke Biotechnology Triple negative breast cancer, Esophagus cancer, Urothelial cancer, Lung cancer, Lymphoma Details
HLX-10 HLX-10,HLX10 Phase Ⅲ Shanghai Henlius Biotech Non small cell lung cancer (NSCLC), Solid tumours Details
MGD-019 (MacroGenics) MGD-019 Phase Ⅰ MacroGenics Solid tumours Details
IBI318 IBI318; IBI-318 Phase Ⅰ Innovent Biologics, Lilly Malignancies Details
Recombinant humanized anti-PD-1 monoclonal antibody (Sinocelltech) SCT-I10A Phase Ⅰ Sinocelltech Solid tumours, Lymphoma Details
PF-06801591 PF-06801591; PF-6801591; RN-888 Phase Ⅰ Pfizer Solid tumours Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) Phase Ⅱ Shanghai Cell Therapy Research Institute Solid tumours Details
CS-17938 CS17938 Preclinical ChipScreen Immunological disorders, Cancer Details
IBI315 IBI-315; IBI315 IND Filing Innovent Biologics, Hanmi Unspecified Details
RB-0004 RB-0004,RB0004; RB 0004 Phase Ⅰ Reyoung Pharmaceutical Malignancies Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) IND Filing Shanghai CP Guojian Unspecified Details
JTX-4014 (Jounce Therapeutics) JTX-4014 Phase Ⅰ Jounce Therapeutics Cancer Details
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) Phase Ⅱ Anhui Kedgene Biotechnology, Hangzhou Cancer Hospital Esophagus cancer Details
KEYNOTE-240 KEYNOTE-240 Phase Ⅲ Merck Sharp & Dohme Hepatocellular carcinoma (HCC) Details
CMAB-819 CMAB8-19,CMAB819; CMAB8 19 Phase Ⅰ SinoMab Bioscience Ltd, Taizhou Mabtech Non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC) Details
CX-188 IND Filing CytomX Therapeutics Cancer Details
LY-3434172 LY-3434172 Phase Ⅰ Lilly Solid tumours Details
PD-1 knockout engineered T cells (Cell Biotech) Phase Ⅰ Cell Biotech Renal cell carcinoma, Prostate cancer, Bladder cancer Details
PD-1 knockout engineered T cells (Chengdu MedGenCell) Phase Ⅱ Chengdu MedGenCell Lung cancer, Melanoma Details
GLS-010 GLS-010,GLS010 Phase Ⅱ Gloria Pharmaceuticals, WuXi AppTec, Arcus Biosciences Triple negative breast cancer, Gastric cancer, Solid tumours, Liver cancer, Hodgkin lymphoma Details
MEDI-5752 MEDI-5752 Phase Ⅰ MedImmune Solid tumours Details
MGD-013 MGD-013,PD-1 X LAG-3,MGD013; MGD 013 Phase Ⅰ MacroGenics, Zai Lab hematological malignancies, Solid tumours Details
Tislelizumab BGB-A317,BGBA317 BLA Filing BeiGene, Celgene, Boehringer Ingelheim Nasopharyngeal cancer, Esophageal squamous cell carcinoma, Non small cell lung cancer (NSCLC), Gastric cancer, Urothelial cancer, Hepatocellular carcinoma (HCC), Microsatellite instability-high cancer, Hodgkin lymphoma Details
Budigalimab ABBV-181; PR-1648817 Phase Ⅰ Abbvie Solid tumours Details
LZM-009 LZM-009,LZM009 Phase Ⅰ Livzon Group Livzon Pharmaceutical Factory Solid tumours Details

This web search service is supported by Google Inc.